國家衛生研究院 NHRI:Item 3990099045/10257
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 917435      Online Users : 1404
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10257


    Title: Role of epigenetic regulator EHMT2 in the regulation of gemcitabine resistance in pancreatic cancer
    Authors: Hung, WC;Pan, MR;Hsu, MC;Chen, LT;Shan, YS
    Contributors: National Institute of Cancer Research
    Abstract: Background: Epigenetic regulation plays an important role in the initiation, promotion and progression of cancers. The alterations of DNA methylation and histone modification are frequently found in pancreatic cancer. However, their contribution to gemcitabine resistance is relatively unclear. Method: We investigated the expression of epigenetic regulators in PANC 1 and gemcitabine-resistant PANC-1 human pancreatic cancer cells by PCR-array. The role of the epigenetic regulators in the control of gemcitabine resistance was addressed by genetic manipulation or chemical inhibitors, and various functional assays were performed to elucidate the underlying mechanism. Results: We have identified EHMT2, a histone H3 lysine 9 (H3K9) methyltransferase, as a potential gene involved in gemcitabine resistance. Overexpression of this gene increased drug resistance in parental cells while knockdown sensitized resistant cells to gemcitabine. In addition, EHMT2 contributed to the stemness properties of pancreatic cancer cells. Finally, our animal study clearly demonstrated that the EHMT2 inhibitor could override the gemcitabine resistance in vivo. Conclusion: EHMT2 is upregulated in gemcitabine-resistant pancreatic cancer cells and is a potential target to overcome the resistance for cancer therapy.
    Date: 2016-11
    Relation: Journal of Gastroenterology and Hepatology. 2016 Nov;31(Suppl. 3):245.
    Link to: http://dx.doi.org/10.1111/jgh.13540
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0815-9319&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000386776002091
    Appears in Collections:[Wen-Chun Hung] Conference Papers/Meeting Abstract
    [Li-Tzong Chen] Conference Papers/Meeting Abstract

    Files in This Item:

    File Description SizeFormat
    ISI000386776002091.pdf140KbAdobe PDF436View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback